Global PLK Targeted Therapies Market Opportunity & Clinical Trials Insight 2024 - Groundbreaking Advances in PLK Targeted Therapies Promise to Revolutionize Treatment for Cancer and Other ...
Cardiff Oncology, Inc. (CRDF)
Company Research
Source: Yahoo! Finance
Global PLK Targeted Therapies Market Opportunity & Clinical Trials Insight 2024 Report Highlights: PLK Targeted Therapies in Clinical Trials: 10 Therapies USA Domination PLK Therapies Clinical Development Landscape: 5 Therapies Breast Cancer Targeted Therapies in Clinical Trials: 5 Therapies PLK Targeted Therapies Clinical Trials Insight by Company, Country, Indication & Phase Insight on Key Companies Involved in Development of PLK Therapies PLK Targeted Therapy Combination Strategies with Chemotherapies, Immunotherapies & Targeted Therapies Polo-like kinases (PLKs) are a group of serine/threonine kinases that play important roles in a variety of cellular processes, including cell cycle regulation, mitosis, DA damage response, and cytokinesis. Because of their role in these crucial processes, PLKs have emerged as promising therapeutic targets in cancer and other diseases. Though the market for PLK targeted therapies is still in its early stages, several pharmaceutica
Show less
Read more
Impact Snapshot
Event Time:
CRDF
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRDF alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRDF alerts
High impacting Cardiff Oncology, Inc. news events
Weekly update
A roundup of the hottest topics
CRDF
News
- Cardiff Oncology to Present at Upcoming Investor Conferences in MayGlobeNewswire
- Cardiff Oncology, Inc. (NASDAQ: CRDF) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $14.00 price target on the stock.MarketBeat
- Cardiff Oncology First Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]Yahoo! Finance
- Cardiff Oncology, Inc. (NASDAQ:CRDF) Q1 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
CRDF
Earnings
- 5/2/24 - Beat
CRDF
Analyst Actions
- 5/6/24 - HC Wainwright
CRDF
Sec Filings
- 5/2/24 - Form 8-K
- 5/2/24 - Form 10-Q
- 4/25/24 - Form DEFA14A
- CRDF's page on the SEC website